About Jenrin Discovery

Jenrin Discovery is developing potential therapeutics for chronic diseases including NAFLD/NASH, diabetes and obesity. Its focus is proprietary small molecule drugs designed to selectively target peripheral receptors. It has completed pre-clinical testing and GLP safety studies for its lead compound, JD5037, and is planning on filing the IND application by the second quarter in 2017. This agent provides a mechanism of action to treat NASH and related pathologies.
visit | email 

Key People

Robert J Chorvat
CSO and Co-Founder

Ross Barrett